All In Biotech

Drug Trial Radar · NCT00465972

The Treatment of Insomnia in Patients With HIV Disease

A Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of Doxepin and Temazepam in HIV Seropositive Patients With Insomnia.

Last checked: Nov 20, 2026Latest source record: Jul 30, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

44

Actual

Start

Mar 2007

Primary completion

Aug 2010

Study completion Aug 2010

Sponsor

Lead sponsor
Duke UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 27, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 69 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to evaluate the efficacy of two commonly prescribed sleep aids for use in patients who are HIV positive and suffer from insomnia.

Conditions

  • HIV Infections
  • Insomnia

Interventions

  • DoxepinDrug

    Doxepin 10 mg po nightly x duration of study length OR Temazepam 15 mg po nightly x duration of study length OR Placebo nightly x duration of study length

  • TemazepamDrug

    Temazepam capsule 15 mg po nightly x duration of study

  • PlaceboDrug

    Placebo capsule nightly for duration of study

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Response: Change in Insomnia Severity Rating Scale at 3 Months.Time frame: Baseline and 3 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Duke University Medical Center

    Durham, North Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.